On August 26, 2024, Regeneron Pharmaceuticals released an announcement that the European Commission had approved Ordspono (odronextamab) for the treatment of adult patients with refractory follicular lymphoma or relapsed or diffuse large B-cell lymphoma (DLBCL) who have received two or more systemic therapies. This bispecific antibody, designed to link lymphoma cells with T cells for a targeted immune response, marks Ordspono's first global regulatory approval. High objective response rates were observed in clinical trials, with a 73% complete response rate in follicular lymphoma patients and optimistic outcomes in post-CAR-T DLBCL patients. Cytokine release syndrome, neutropenia, and infections are among the most prevalent adverse effects, emphasizing the necessity of meticulous patient monitoring.
Regeneron, a leading biotechnology company, is known for its innovative medicines addressing serious diseases, including cancer, eye, cardiovascular, and rare diseases. Ordspono is the first approval from Regeneron’s bispecific antibody platform, which the company plans to expand through its OLYMPIA program and broader pipeline targeting hematologic and solid tumors. Regeneron’s proprietary technologies, including VelociSuite and the Regeneron Genetics Center, enable it to pioneer next-generation therapies, combining cutting-edge science and genetic medicine to advance treatments in oncology and other fields.
